Zhejiang Garden Biopharmaceutical Adjusts Valuation Amidst Quality Score Reassessment
Zhejiang Garden Biopharmaceutical Co., Ltd. has recently experienced a change in its overall evaluation, influenced by adjustments in valuation and quality metrics. The company shows a fair valuation with manageable debt levels, while its operational performance has led to a reassessment of its quality score.
Zhejiang Garden Biopharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects changes in both its valuation and quality metrics, which have prompted a reassessment of its overall score.The valuation indicators show a P/E ratio of 23, alongside a price-to-book value of 2.20. The company’s EV to EBIT stands at 22.26, while the EV to EBITDA is recorded at 15.07. These figures suggest a fair valuation in the current market context. Additionally, the PEG ratio is noted at 0.45, indicating a potentially favorable growth outlook relative to its earnings.
On the quality front, the company has demonstrated a sales growth rate of 14.59% over the past five years, with EBIT growth at 5.07%. The debt metrics appear manageable, with a debt-to-EBITDA ratio of 0.40 and a net debt to equity ratio of 0.12. However, the overall quality score has been adjusted to average, reflecting a more cautious view of its operational performance.
In light of these developments, stakeholders may find it beneficial to monitor the evolving financial landscape of Zhejiang Garden Biopharmaceutical Co., Ltd.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read
